Member States of the World Health Organization (WHO) have progressed work on the Pathogen Access and Benefit Sharing (PABS) annex, a key part of the WHO Pandemic Agreement, and today agreed additional time was needed to finalize the framework for ensuring a better, more equitable, response to future pandemics.Countries today ended the resumed session of the sixth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement in Geneva, focused on the PABS system. The outcome of this work will be presented to the Seventy-ninth World Health Assembly (WHA) later this month. Given the need for further negotiations, the Assembly will be asked to consider continuing IGWG’s work as mandated in Resolution WHA78.1 and submit the outcome to the next Assembly in May 2027, or earlier by a special session of WHA in 2026.“Real progress was made on the PABS annex and I am confident through continued negotiations differences will be overcome,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Member States should continue approaching the outstanding issues with a sense of urgency because the next pandemic is a matter of when, not if. The PABS annex is the last piece of the puzzle not only for the Pandemic Agreement but all initiatives that WHO and Member States have implemented as a result of lessons learned from the COVID-19 pandemic.”The PABS system is intended to ensure, on equal footing, the rapid sharing of pathogens with pandemic potential and the fair and equitable sharing of benefits arising from their use, such as vaccines, diagnostics and therapeutics. Finalizing the PABS Annex is necessary so countries can proceed with signature and ratification of the Pandemic Agreement. “Finalizing a document of such technical and legal complexity requires precision and dedication, both of which the Member States have demonstrated in full,” said IGWG Bureau Co-Chair Ambassador Tovar da Silva Nunes of Brazil. “We are not there yet, but with an extension of our negotiations, we will get there.”IGWG Co-Chair Mr Matthew Harpur said: “WHO Member States have demonstrated strong and continuing commitment to negotiations on a Pathogen Access and Benefit Sharing system annex. The IGWG Bureau is confident we are moving in the right direction to finalize the PABS annex, and in doing so provide the WHO Pandemic Agreement with the framework needed to ensure countries are better, and more equitably, prepared and protected for the next pandemic.”The IGWG will hold its seventh meeting from 6 to 17 July 2026.In May 2025, the World Health Assembly adopted the WHO Pandemic Agreement to strengthen how countries prevent, prepare for, and respond to pandemics. It also established an open-ended Intergovernmental Working Group (IGWG) to carry out key tasks, including drafting and negotiating the PABS system.   

The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health Organization (WHO) report released today at the World Hepatitis Summit.Viral hepatitis B and C – the two infections responsible for 95% of hepatitis-related deaths worldwide – claimed 1.34 million lives in 2024, the latest data show. At the same time, transmission continues, with more than 4900 new infections every day, or 1.8 million each year.The 2026 Global hepatitis report documents significant gains made since 2015. The annual number of new hepatitis B infections has dropped by 32% and hepatitis C-related deaths have fallen by 12% globally. Hepatitis B prevalence among children under five has also decreased to 0.6%, with 85 countries achieving or surpassing the 2030 target of 0.1%.These achievements reflect the impact of sustained, coordinated global and national action following the adoption of WHO viral hepatitis elimination targets by Member States at the World Health Assembly in 2016. However, the report warns that current rates of progress are insufficient to meet all 2030 elimination targets, underscoring the urgent need to accelerate prevention, testing, and treatment efforts worldwide.“Around the world, countries are showing that eliminating hepatitis is not a pipedream, it's possible with sustained political commitment, backed by reliable domestic financing,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “At the same time, this report shows that progress is too slow and uneven. Many people remain undiagnosed and untreated due to stigma, weak health systems and inequitable access to care. While we have the tools to eliminate hepatitis as a public health threat, urgent scale-up of prevention, diagnosis and treatment is needed if the world is to meet the 2030 targets.”Global burden and gaps in responseUpdated WHO estimates indicate that 287 million people were living with chronic hepatitis B or C infection in 2024.That year, 0.9 million people were newly infected with hepatitis B. The WHO African Region accounted for 68% of new hepatitis B infections, yet only 17% of newborns in the region received the hepatitis B birth-dose vaccination.A further 0.9 million hepatitis C infections were recorded in 2024. People who inject drugs accounted for 44% of new infections, highlighting the urgent need for stronger harm reduction services and safe injection practices.Of the 240 million people with chronic hepatitis B in 2024, fewer than 5% were receiving treatment. Only 20% of people with hepatitis C have been treated since 2015, when a new 12-week treatment with a cure rate of about 95% became available.As a result of limited access to prevention and care, in 2024 an estimated 1.1 million people died from hepatitis B and 240 000 from hepatitis C. Liver cirrhosis and hepatocellular carcinoma were the main causes of hepatitis related deaths. A large share of hepatitis B-related deaths occurred in the African and Western Pacific Regions.Ten countries – Bangladesh, China, Ethiopia, Ghana, India, Indonesia, Nigeria, the Philippines, South Africa and Viet Nam – accounted for 69% of hepatitis B related deaths worldwide in 2024. Hepatitis C-related deaths are more geographically dispersed. In 2024, ten countries accounted for 58% of the global total: China, India, Indonesia, Japan, Nigeria, Pakistan, the Russian Federation, South Africa, the United States of America and Viet Nam.Proven solutionsDespite these challenges, progress in countries such as Egypt, Georgia, Rwanda, and the United Kingdom demonstrates that eliminating hepatitis as a public health problem is achievable with sustained commitment and investment.Highly effective tools are already available:hepatitis B vaccine protects more than 95% of vaccinated people against both acute and chronic infections;long-term antiviral treatment for hepatitis B can help effectively manage chronic infection and prevent severe liver disease; and hepatitis C short-course curative therapy lasting 8-12 weeks can cure more than 95% of infections.“The data shows that progress is possible but also reveals where we are falling short. Every missed diagnosis and untreated infection due to chronic viral hepatitis represents a preventable death,” said Dr Tereza Kasaeva, Director, WHO Department for HIV, TB, Hepatitis and Sexually Transmitted Infections. “Countries must move faster to integrate hepatitis services for people living with hepatitis B and C into primary care, and to reach the communities most affected.”The report identifies priority actions to accelerate hepatis elimination as a public health threat. These include scaling up treatment for chronic hepatitis B infection, particularly in the WHO African and Western Pacific regions, and expanding access to hepatitis C treatment in the WHO Eastern Mediterranean Region.It also calls for stronger political commitment and financing, improved coverage of hepatitis B birth-dose vaccination and expanded antiviral prophylaxis to prevent mother-to-child transmission of HBV infection, particularly in the WHO African Region. In addition, the report emphasizes the need to improve injection safety in both health-care settings and community practices, including through strengthened harm reduction services for people who inject drugs. 

The World Health Organization (WHO) wrapped up Exercise Polaris II, a 2-day high-level simulation exercise, based around an outbreak of a fictional new bacterium spreading across the world. Bringing together 26 countries and territories, 600 health emergency experts and over 25 partners, the exercise, which took place on 22 and 23 April, allowed countries to test their preparedness for pandemics and other major health emergencies, including activating their emergency workforce structures, information flow and coordination with each other, partners and WHO.Building on the success of Polaris I held in April 2025, which centered on a fictional virus, each participating country activated its emergency coordination structure and worked under real-life conditions to share information, align policies and surge their workforce.“Exercise Polaris II showed what is possible when we act together. It demonstrated that global cooperation is not optional – it is essential,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is the purpose of the Global Health Emergency Corps: coordination across the emergency workforce, building trust, strengthening connections, and working as one across borders.”The simulation put two key WHO frameworks into practice, the Global Health Emergency Corps (GHEC) framework and the National health emergency alert and response framework, and explored the use of AI-enabled tools to support workforce organization and planning.The GHEC framework, published in June 2025, provides guidance on how countries can strengthen their health workforce to respond to emergencies based on the principles of sovereignty, equity and solidarity. It improves collaboration between countries by supporting information exchange and strengthening the deployment of regional and global emergency personnel when needed.The National health emergency alert and response framework, published in October 2025 outlines the key functions, coordination systems and actions needed for an effective response at local, sub-national and national levels.“By simulating the spread of a dangerous pathogen under real-life conditions, Exercise Polaris II helped us turn existing plans into action. It is not enough to have plans on paper – what matters is how they perform in practice,” said Edenilo Baltazar Barreira Filho, Director of the Public Health Emergencies Department, Ministry of Health, Brazil. The exercise also provided an opportunity to practice a coordinated provision of technical expertise and surge support to countries from over 25 national, regional and global health agencies and organizations, including Africa Centres for Disease Control and Prevention, the International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières, Robert Koch Institute, UK-Med, UNICEF, and emergency networks such as the Global Outbreak Alert and Response Network, the Emergency Medical Teams initiative, Standby Partners, and the International Association of National Public Health Institutes.“Exercise Polaris II showed what it looks like when countries are prepared and ready to act together,” said Dr Chikwe Ihekweazu, Executive Director of WHO’s Health Emergencies Programme. “This reflects the spirit of the Global Health Emergency Corps: a well-organized, trained, coordinated and connected emergency workforce ready to respond wherever and whenever it is needed.”The second edition of the exercise saw a larger number of countries participate and collaborate through new networks such as the recently launched Health Emergency Leaders Network for Africa and the Eastern Mediterranean.Exercise Polaris II is part of HorizonX, WHO’s forward-looking, multi-year simulation exercise programme. It provides a vital platform to operationalize and practice emergency frameworks under real-life conditions, ensuring that collective readiness is not a periodic effort, but a continuous investment in global health security. Note to editorsParticipating countries and territories covering all WHO regions included Bangladesh, Brazil, Brunei, Colombia, Egypt, El Salvador, France, Georgia, Ghana, India, Indonesia, Jordan, Kenya, Kosovo*, Libya, Malaysia, Nepal, Oman, Paraguay, Philippines, Qatar, Republic of Congo, Rwanda, Suriname, Thailand, and Yemen.*All references to Kosovo on this page should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).About WHODedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the United Nations’ agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable.  “Together for health. Stand with science”, the theme of World Health Day 2026 marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide. 

Ahead of World Malaria Day on 25 April, the World Health Organization (WHO) has announced a significant step forward in the fight against malaria with the prequalification of the first treatment developed specifically for newborns and young infants weighing between two and five kilograms. The prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy, and will help to expand access to quality-assured treatment for one of the most underserved patient groups.The newly prequalified treatment, artemether-lumefantrine, is the first antimalarial formulation designed specifically for the youngest malaria patients. Until now, infants with malaria have been treated with formulations intended for older children, which increase the risk of dosing errors, side effects and toxicity. WHO prequalification will enable public sector procurement, contributing to closing a long-standing treatment gap for some 30 million babies born each year in malaria-endemic areas of Africa."For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide. Ending malaria in our lifetime is no longer a dream – it is a real possibility, but only with sustained political and financial commitment. Now we can. Now we must."New prequalified testsOn 14 April 2026, WHO also prequalified three new rapid diagnostic tests (RDTs) designed to address emerging diagnostic challenges for malaria. The most common malaria RDTs for P.falciparum parasite work by detecting the protein, known as HRP2. But based on reported studies and surveys in 46 countries, some strains of the malaria parasite have lost the gene that makes this protein – so they become "invisible" to HRP2-based RDTs, leading to false-negative results. In countries in the Horn of Africa, up to 80% of cases were missed, leading to delayed treatment, severe illness, and even death.The new tests address this issue by targeting a different parasite protein (pf-LDH) that the malaria parasite cannot easily shed. They provide a reliable, quality-assured alternative where HRP2-based tests are failing. WHO now recommends that countries switch to these alternative RDTs when more than 5% of cases are missed due to pf-hrp2 deletions. This ensures accurate diagnosis, appropriate treatment, and protects hard-won malaria control gains – especially for the most vulnerable communities.The announcements come as WHO and partners launch the 2026 World Malaria Day campaign, "Driven to End Malaria: Now We Can. Now We Must." The theme is a rallying cry to seize the moment – to protect lives now and fund a malaria-free future.According to the World malaria report 2025, there were an estimated 282 million cases and 610 000 deaths in 2024 – an increase from 2023. While 47 countries have been certified malaria-free and 37 countries reported fewer than 1000 cases in 2024, progress at the global level is stalling. Gains are at risk due to multiple challenges, including drug resistance, insecticide resistance, diagnostic failure, and severe reductions in international development assistance.Despite these challenges, substantial progress has been made, with an estimated 2.3 billion malaria infections prevented and 14 million lives saved worldwide since 2000.Twenty-five countries are now rolling out malaria vaccines, protecting millions of children, and next-generation mosquito nets make up 84% of all new nets distributed. These advances demonstrate what is possible when all partners work together to innovate and deliver on the promises towards ending malaria for all. About WHODedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable.“Together for health. Stand with science”, the theme of World Health Day 2026 marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide.